Damon Runyon Cancer Research Foundation

Damon Runyon launches new pediatric cancer fellowship in partnership with St. Jude Children’s Research Hospital

Retrieved on: 
Thursday, June 8, 2023

NEW YORK, N.Y. and MEMPHIS, Tenn., June 08, 2023 (GLOBE NEWSWIRE) -- The Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital announced a new pediatric-focused fellowship today.

Key Points: 
  • NEW YORK, N.Y. and MEMPHIS, Tenn., June 08, 2023 (GLOBE NEWSWIRE) -- The Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital announced a new pediatric-focused fellowship today.
  • Jude Pediatric Cancer Research Fellowship will fund up to 25 fellowships over eight years, a $9 million investment.
  • “Damon Runyon is uniquely positioned to identify gaps in the cancer research landscape, and the underfunding of pediatric cancer research has been a concern of ours for years,” said Yung S. Lie, Ph.D., President and CEO of the Damon Runyon Cancer Research Foundation.
  • To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today's best young scientists with funding to pursue innovative research.

Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Retrieved on: 
Thursday, April 13, 2023

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced a licensing agreement with MSK.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced a licensing agreement with MSK.
  • “We are committed to pushing forward a first-in-class pipeline of treatments targeting oncogene driver mutations for patients with solid tumor malignancies,” said Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, Affini-T Therapeutics.
  • Dr. Klebanoff has contributed to the successful early phase development of numerous T cell-based therapies, notably Yescarta® (axicabtagene ciloleucel) at NCI.
  • “As a practicing medical oncologist, my singular professional focus and that of my lab is to address the urgent needs of patients with cancer.

IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors

Retrieved on: 
Thursday, June 23, 2022

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the appointment of William G. Kaelin Jr., M.D., to its Board of Directors.

Key Points: 
  • IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the appointment of William G. Kaelin Jr., M.D., to its Board of Directors.
  • Dr. Kaelin will continue to serve as a member of IconOVirs Scientific Advisory Board.
  • Over the past year, we have benefited greatly from Bills insights as a member of our Scientific Advisory Board.
  • IconOVir is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

Retrieved on: 
Monday, November 22, 2021

Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs.

Key Points: 
  • Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs.
  • Were pleased to welcome Richard to our Board, said Dr.Samantha Du, Founder, Chairperson and Chief Executive Officer ofZai Lab.
  • Its an honor to join the Zai Lab Board and to work alongside Samantha and her team in achieving the companys vision of becoming a global biopharmaceutical company, commented Dr. Gaynor.
  • Were excited by the collective expertise the Board will bring to Zai Lab as we strengthen our capabilities and execute our global strategy.

Navy SEAL Foundation Earns Charity Navigator's 4-Star Rating for Tenth Consecutive Year

Retrieved on: 
Friday, February 19, 2021

Michael A. Thatcher, Charity Navigator's President & CEO, informed the Navy SEAL Foundation's management staff and board of directors about the impressive distinction--its tenth consecutive 4-Star rating.

Key Points: 
  • Michael A. Thatcher, Charity Navigator's President & CEO, informed the Navy SEAL Foundation's management staff and board of directors about the impressive distinction--its tenth consecutive 4-Star rating.
  • Attaining a 4-star rating verifies that Navy SEAL Foundation exceeds industry standards and outperforms most charities in your area of work."
  • About the Navy SEAL Foundation:
    The Navy SEAL Foundation's mission is to provide immediate and ongoing support and assistance to the Naval Special Warfare (NSW) community and its families.
  • Charity Navigator, http://www.charitynavigator.org , is the largest charity evaluator in America, and its website attracts more visitors than all other charity rating groups combined.

Damon Runyon Cancer Research Foundation Announces First-Ever Stair Climb at Salesforce Tower on October 21, 2018

Retrieved on: 
Monday, September 24, 2018

SAN FRANCISCO, Sept. 24, 2018 On Sunday, October 21, 2018, the Damon Runyon Cancer Research Foundation, in partnership with Boston Properties (NYSE: BXP), will host Runyon Up, a stair climb at the new Salesforce Tower in San Francisco, to raise funds for innovative cancer research.

Key Points: 
  • SAN FRANCISCO, Sept. 24, 2018 On Sunday, October 21, 2018, the Damon Runyon Cancer Research Foundation, in partnership with Boston Properties (NYSE: BXP), will host Runyon Up, a stair climb at the new Salesforce Tower in San Francisco, to raise funds for innovative cancer research.
  • Salesforce Tower is a symbol of innovation, an appropriate venue to champion our commitment to the cutting-edge researchers who are making the medical breakthroughs of tomorrow," said Lorraine W. Egan, President and Chief Executive Officer of the Damon Runyon Cancer Research Foundation.
  • To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today's best young scientists with funding to pursue innovative cancer research.
  • Twelve Damon Runyon scientists have received the Nobel Prize and countless others have made discoveries that are saving lives today.

Yung S. Lie, PhD, Named Next President and CEO of the Damon Runyon Cancer Research Foundation

Retrieved on: 
Wednesday, August 15, 2018

NEW YORK, Aug. 15, 2018 /PRNewswire/ -- Chairman Alan M. Leventhal of the Damon Runyon Cancer Research Foundation today announced the appointment of Yung S. Lie, PhD, as incoming Damon Runyon President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Aug. 15, 2018 /PRNewswire/ -- Chairman Alan M. Leventhal of the Damon Runyon Cancer Research Foundation today announced the appointment of Yung S. Lie, PhD, as incoming Damon Runyon President and Chief Executive Officer.
  • Lie, currently Deputy Director and Chief Scientific Officer of Damon Runyon, is the first scientist and Damon Runyon alumna to lead the organization since it was founded in 1946.
  • Lie as the next President and CEO of Damon Runyon.
  • To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today's best young scientists with funding to pursue innovative cancer research.